Tenofovir Disoproxil Fumarate + LamivudineThird Party Manufacturing in India

Tenofovir Disoproxil Fumarate + Lamivudine works through the synchronized inhibition of viral reverse transcriptase by two distinct nucleotide/nucleoside analogues. Once intracellularly phosphorylated, Tenofovir diphosphate and Lamivudine triphosphate compete with natural substrates for incorporation into viral DNA. They act on these viral targets to help the body cause premature DNA chain termination and halt retroviral replication cycles. Unlike monotherapy, this dual-NRTI backbone provides a high genetic barrier to viral resistance. It is highly effective and well-tolerated in standard long-term therapy designs.

Therapeutic Uses

• HIV-1 Combination Therapy: Acts as a standardized dual-nucleoside backbone regimen for treating human immunodeficiency virus type-1.
• HBV/HIV Co-infection: Offers simultaneous therapeutic control of both HIV and chronic Hepatitis B replication profiles.
• Prophylactic Regimens: Integrated into post-exposure prophylaxis programs to prevent viral seroconversion after occupational contact.

Why Manufacturers Choose Tenofovir Disoproxil Fumarate + Lamivudine

Tenofovir Disoproxil Fumarate + Lamivudine third party manufacturing in India represents a cornerstone product for international healthcare tenders and institutional supply chains. Fabricating these high-dose combination tablets requires expert handling of bulk powder flow properties and compression durability. Our partner facilities manage dedicated, large-scale antiviral manufacturing lines operating under rigorous WHO-GMP guidelines, assuring impeccable chemical purity and optimal tablet dissolution profile consistency.